 |
|
|
Development Partnerships
Aventis (now Sanofi-Aventis, NYSE: SNY) and Avalon Pharmaceuticals, Inc viagra., have entered into an agreement to collaborate on the identification, discovery and validation of drugable screening targets generic viagra online. Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines cialis. |
|
 |
|
| Medarex, Inc . (Nasdaq: MEDX) and Avalon Pharmaceuticals, Inc. have entered into an agreement under which the two companies will collaborate on the planned development of antibody products. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody related capabilities, including pre-clinical and clinical development supported by cGMP manufacturing services . |
|
 |
|
| MedImmune, Inc. (Nasdaq: MEDI) and Avalon have entered into an agreement under which the companies will collaborate to discover and develop small molecule therapeutic compounds in the area of inflammatory disease. Under the terms of the agreement, we will use AvalonRx™ to identify lead compounds. MedImmune will be responsible for preclinical and clinical testing of any resulting product candidates, as well as all future development, sales and marketing activities. |
|
 |
|
| Novartis Institutes for Biomedical Research, Novartis' global research organization (NYSE: NVS), and Avalon have entered into an agreement under which the companies will discover small molecule therapeutic compounds targeted against a pathway selected by Novartis. Avalon will use its AvalonRx® drug discovery engine in this pilot study to identify hits from compounds in Novartis' chemical library. Novartis will be responsible for lead optimization, preclinical and clinical testing of any resulting product candidates, as well as all future development and sales and marketing activities. |
|
 |
|
| Vertex Pharmaceuticals (Nasdaq: VRTX) and Avalon have entered into an agreement where Vertex has licensed Avalon the IMPDH inhibitor, AVN944. Avalon holds exclusive rights to develop and commercialize AVN944 worldwide for the treatment or prevention of cancer. |
|
Collaborations: Other Partners/Academic Collaborators
Gene Logic, Asinex, University of Texas Southwestern Medical Center, Henry M. Jackson Foundation for the Advancement of Military Medicine (Center for Prostate Disease Research/ Walter Reed Army Medical Center, Washington DC)
|
|
|
|
